Stocks in play: Revive Therapeutics Ltd

Announced today that the U.S. Food & Drug Administration has granted the Company’s Type C meeting request to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The goal date for the FDA to provide its written responses is March 7, 2023. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 at this time. Revive Therapeutics Ltd shares C.RVV are trading up 4.5% at $0.11.

Read:

• Addressing the USA’s 200 to 1 Security Protection Gap is a Serious Concern for Tech Companies

• Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector

• Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

• Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

• New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates